Tripartite motif-containing protein 6 (TRIM6)

Tripartite motif-containing protein 6 (TRIM6) is a nuclear-localized E3 ubiquitin ligase characterized by three zinc-binding domains (RING, B-box type 1 and 2) and a coiled-coil region[3][4][5]. TRIM6 catalyzes the formation of unanchored K48-linked polyubiquitin chains, which activate kinases (like IKKε), promote STAT1 phosphorylation, and induce antiviral gene expression[2][4]. It is integral to the innate immune response and is exploited or degraded by certain viral proteins, reducing host antiviral signaling[2][4]. In cancer biology, TRIM6 promotes epithelial-mesenchymal transition (EMT) and cell invasion, notably via upregulation of Snail1, linking it to metastasis[1]. TRIM6 also interacts with and ubiquitinates DDX58 (RIG-I), affecting anti-viral and cancer-relevant pathways[1]. TRIM6 is considered a therapeutic target, particularly in oncology and infectious disease, due to its roles in EMT and innate immunity[1][2][4]. No direct drug interactions or approved therapeutics are reported in available sources, and its biomarker utility is currently undefined. Safety concerns relate primarily to its central role in immune defense and cell signaling, making it a challenging but potentially impactful therapeutic target.

Other names

TRIM6RNF89RING finger protein 89RING-type E3 ubiquitin transferase TRIM6

E3 ubiquitin ligase activity mediating ubiquitination and proteasomal degradation of target proteins such as DDX58 (RIG-I); Facilitates induction of interferon-stimulated genes through activation of IKBKE and STAT1